Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

(2013) T. Heise et al.   DIABETES OBESITY & METABOLISM

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area

(2012) Gabriel Coll-de-Tuero et al.   BMC Nephrology

Evolving Treatment Strategies for the Management of Type 2 Diabetes

(2011) William T. Cefalu   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

(2011) David R. Whiting et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Overview of Newer Agents: Where Treatment Is Going

(2010) Ralph A. DeFronzo   AMERICAN JOURNAL OF MEDICINE

Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States

(2010) Carol E. Koro et al.   CLINICAL THERAPEUTICS

Definition and Classification of CKD: The Debate Should Be About Patient Prognosis—A Position Statement From KDOQI and KDIGO

(2009) Kai-Uwe Eckardt et al.   AMERICAN JOURNAL OF KIDNEY DISEASES